L-Cysteine Capsule for Alcohol Flushing Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alcohol-induced flushing and hypersensitivity reactions in individuals with ALDH2 deficiency are not effectively addressed by existing technologies, as they primarily focus on blood acetaldehyde levels rather than local acetaldehyde-mediated histamine release in the digestive tract.
Innovation Solution
Slowly releasing L-cysteine preparations that bind acetaldehyde in the stomach or mouth, forming inactive products and reducing histamine release, thereby preventing and treating alcohol-induced flushing and hypersensitivity reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments focus on reducing blood acetaldehyde levels, then systemic acetaldehyde toxicity is addressed, but local acetaldehyde-mediated histamine release in the digestive tract is not effectively prevented
Solution Approach 1:
The invention applies local quality by delivering cysteine specifically to the digestive tract where acetaldehyde is produced by oral microbes and mucosal cells. The capsule formulation ensures cysteine is released in the stomach and upper digestive tract, creating high local concentrations where they are needed to bind acetaldehyde and prevent histamine release, rather than relying on systemic distribution alone.
Solution Approach 2:
Cysteine acts as an intermediary substance that binds to acetaldehyde in the digestive tract, forming a non-toxic complex. This intermediary mechanism directly addresses local acetaldehyde production by providing a binding agent at the site of acetaldehyde generation, preventing the acetaldehyde-histamine interaction that causes flushing and hypersensitivity reactions.
2Object-affected harmful factors
If acetaldehyde is bound in the digestive tract, then histamine release is reduced, but the treatment requires specific delivery mechanisms to ensure adequate cysteine concentration at the site of acetaldehyde production
Solution Approach 1:
The treatment employs preliminary action by administering the cysteine capsule before alcohol consumption. This ensures that cysteine is already present in the digestive tract and can immediately bind to acetaldehyde as it is produced from alcohol metabolism, preventing the formation of acetaldehyde-histamine complexes before they can trigger flushing and hypersensitivity reactions.
Solution Approach 2:
The invention uses a simple, disposable capsule formulation containing cysteine. This single-use delivery system is inexpensive and easy to administer, providing a practical solution that does not require complex reusable devices or sophisticated delivery infrastructure, making the treatment accessible and convenient for users.
3Duration of action of moving object
If L-cysteine is released slowly in the stomach, then sustained acetaldehyde binding is achieved, but the release mechanism must be controlled to match alcohol metabolism timing
Solution Approach 1:
The capsule employs periodic action through its controlled release mechanism, which releases cysteine in a sustained manner over time. This periodic release pattern matches the timing of alcohol metabolism and acetaldehyde production, ensuring that cysteine is continuously available to bind acetaldehyde throughout the period when it is being generated, providing sustained protection without requiring complex active control systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The L-cysteine preparations significantly reduce acetaldehyde levels in saliva and gastric juice, effectively alleviating symptoms such as facial redness, increased skin temperature, and cardiovascular responses associated with alcohol consumption, with a prolonged release mechanism ensuring sustained effectiveness.
Implementation Method 1
L-cysteine preparations that bind acetaldehyde in the stomach or mouth, forming inactive products
Implementation Method 2
with a prolonged release mechanism ensuring sustained effectiveness
Data Source
Figure 1~2a
Figure 2b~3a
Figure 3b~4a
AI summary
The present invention relates to a cysteine releasing pharmaceutical preparation(s) for novel use in preventing and/or treating alcohol flushing and alcohol induced hypersensitivity reactions. Additionally, the invention relates to a method for eliminating histamine releasing effect of locally formed acetaldehyde in the digestive tract.